

Government of Western Australia North Metropolitan Health Service Women and Newborn Health Service



ADULT MEDICATION GUIDELINE

BUPRENORPHINE

Scope (Staff): All WNHS Staff

Scope (Area): Obstetrics and Gynaecology

This document should be read in conjunction with the **Disclaimer**.

Quick Links									
Dose	Administration	Monitoring	Pregnancy and Breastfeeding						
Restrictions									
Formulary: Restricted									
HIGH RISK Medication									
Medication Class									
Opioid									
Presentation									
Sublingual Tablet: 200microg Patch: 5microg/hr, 10microg/hr, 15microg/hr, 30microg/hr Ampoule: 300microg/mL									
Products for opioid dependence: Sublingual Tablet: 400microg, 2mg, 8mg Sublingual Film (combination with naloxone): 2mg/0.5mg, 8mg/2mg									
Storage									
Store at room temperature, below 25°C									
Schedule 8 Medication									
Dose									

Moderate-to-severe pain

Acute Pain

Sublingual: 200 - 400microg every 6 to 8 hours

IM/IV: 300 - 600microg every 6 to 8 hours

Chronic Pain

Patch: Seek specialist advice if the patient is already taking an opioid.

Opioid-naive, initially, apply a 5 micrograms/hour patch. Titrate dose to effect by adding a second patch or changing to a higher strength patch. Maximum 40 micrograms/hour.

Do not increase dose at intervals of <3 days.

Change each patch every 7 days.

Opioid Dependence

Refer to KEMH Pharmaceutical and Medicines Management Guideline: <u>Community Programme</u> <u>for Opioid Pharmacotherapy (CPOP) Management in Hospital</u> For more information, please contact <u>KEMH Obstetric Medicines Information Service.</u>

Administration

Sublingual (analgesia)

Place tablet under the tongue and keep in place until dissolved. Do not chew or swallow the tablet.

Sublingual (opioid dependence)

Refer to KEMH Pharmaceutical and Medicines Management Guideline: <u>Community Programme</u> for Opioid Pharmacotherapy (CPOP) Management in Hospital

Patch

Write the date and time of application on the patch with permanent marker, then apply to dry, non-irritated, hairless skin on upper torso. Check the patch is still attached on the days between patch changes.

Remove after 7 days and put a new patch on a different area (avoid re-using the same area for at least 3 weeks).

• Heat increases the release of buprenorphine from patch; avoid exposure to external heat sources (including electric blankets, heat pads, heat lamps, saunas, hot baths).

Do not cut or divide patches as this may affect drug release characteristics.

IV injection

Inject undiluted over at least 2 minutes

IM injection

Suitable

Monitoring

Tolerance and dependence, withdrawal effects, sedation and respiratory depression

Pregnancy

1st Trimester: Considered safe to use

2nd Trimester: Considered safe to use

3rd Trimester: Considered safe to use

Breastfeeding

Considered safe to use

Related Policies, Procedures & Guidelines

KEMH Pharmaceutical & Medicines Management Guidelines:

Community Programme for Opioid Pharmacotherapy (CPOP): Management in Hospital

Restricted Schedule 4 (S4R) and Schedule 8 (S8) Medications

KEMH Clinical Guidelines: O&G

WANDAS

KEMH Clinical Guidelines: Neonatal

Maternal Medication/Substance Use

Neonatal Abstinence Syndrome (NAS)

WA Health:

Guideline on continuation of opioid substitution treatment in hospitals

References

Australian Medicines Handbook. Buprenorphine. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2022 [cited 2022 Feb 28]. Available from: https://amhonline.amh.net.au/

Society of Hospital Pharmacists of Australia. Buprenorphine. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2022 [cited 2022 Feb 28]. Available from: http://aidh.hcn.com.au

The Royal Women's Hospital. Buprenorphine. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2022 [cited 2022 Feb 02]. Available from: https://thewomenspbmg.org.au/

Keywords	Buprenorphine, analgesia, temgesic, norspan, CPOP, opioid replacement, Subutex, Suboxone							
Document Owner:	Chief Pharmacist							
Author/ Reviewer	KEMH Pharmacy Department							
Version Info:	5.0							
Date First Issued:	Nov 2014	Last Reviewed:	Feb 2022		Review Date:	Feb 2025		
Endorsed by:	Medicines and Therapeutics Committee				Date:	13/04/2022		
NSQHS Standards Applicable:	Std 1: Clinical Governance			Std 5: Comprehensive Care				
	Std 2: Partnering with Consumers			Std 6: Communicating for Safety				
	Std 3: Preventing and Controlling Healthcare Associated Infection			Std 7: Blood Management				
	Std 4: Medication Safety			Std 8: Recognising and Responding to Acute Deterioration				
Printed or personally saved electronic copies of this document are considered uncontrolled.								
Access the current version from WNHS HealthPoint.								

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability. © Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.